Posterior Uveitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Posterior Uveitis Market Outlook

Thelansis’s “Posterior Uveitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Posterior Uveitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Posterior Uveitis Overview

Posterior uveitis, a group of disorders characterized by diffuse choroidal inflammation, has multiple risk factors, including genetics, race, geography, and environment. The presence of specific major histocompatibility haplotypes in certain uveitis entities highlights the crucial role of genetic factors in its development. The classification of posterior uveitis into infectious and non-infectious categories is based on the underlying causes; fungal, bacterial, and viral infections (e.g. Candidiasis, Syphilis, Herpes zoster virus, Herpes simplex virus, and Cytomegalovirus) for infectious posterior uveitis and autoimmune diseases (e.g. Lupus erythematosus, White dot syndrome, Wegener granulomatosis, and Sarcoidosis) for non-infectious posterior uveitis. Through its cellular and humoral components, the immune system plays a crucial role in the inflammatory response aimed at removing causes of injury and by-products of injury. Prolonged or inappropriately directed inflammation can cause damage to normal body tissues, leading to disease and morbidity, including permanent visual morbidity commonly caused by recurrent inflammation or prolonged disease (e.g. cystoid macular edema, cataract, glaucoma, retinal detachment, and chorioretinal scarring).

• In the USA, uveitis prevalence is estimated to be 5.4 cases per 1000 in the adult American population aged 20 to 69 years old.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: